<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        7-63-82
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1982
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ISOPTIN TABLETS 80 MG.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VERAPAMIL HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        14.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="FAMAR" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            FAMAR
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Abbott Laboratories
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C08DA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine is used for the treatment of heart diseases associated with an inadequate oxygen supply to the heart muscles, as well as for the treatment of certain arrhythmias (irregular heartbeat) and to treat high blood pressure.</p><p>&nbsp;</p><p>Isoptin 80 mg is used for:</p><ul><li>&nbsp; &nbsp; &nbsp; &nbsp; Disorders (e.g. pain or sensation of tightness in the chest) in conditions involving an inadequate oxygen supply to the heart muscles (angina pectoris):</li></ul><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On exertion: chronic, stable angina pectoris (angina of effort)</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At rest: unstable angina pectoris (crescendo angina, angina at rest)</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vascular constriction: vasospastic angina pectoris (Prinzmetal&rsquo;s angina, variant angina)</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Angina pectoris following a heart attack in patients without heart failure, when treatment with beta blockers is not indicated</p><ul><li>&nbsp; &nbsp; &nbsp; Irregular heartbeat involving:</li></ul><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Episodes of rapid heartbeat starting above the ventricles (paroxysmal supraventricular tachycardia)</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atrial fibrillation / atrial flutter (abnormal heartbeat following increased pathogenic stimulation of the atrium) with rapid AV conduction [except in WPW (Wolff-Parkinson-White) or Lown-Ganong-Levine syndrome]</p><ul><li>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;High blood pressure</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Isoptin 80 mg</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to verapamil hydrochloride or any of the other ingredients of this medicine listed in section 6</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have suffered cardiovascular shock</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe cardiac conduction disorders between the sinus node and atrium [second and third degree SA (sinoatrial) block], unless you have a pacemaker</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe cardiac conduction disorders between the atrium and the ventricles [second and third degree AV (atrioventricular) block], unless you have a pacemaker</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are suffering from sick sinus syndrome (irregular heartbeat following malfunction of the sinus node), e.g. heart rate reduced to less than 60 beats per minute or intermittent delayed or accelerated heartbeat or cardiac conduction disorders between the sinus node and atrium or reduced sinus node stimulation (sinus bradycardia, bradycardia-tachycardia syndrome, SA block or sinus arrest), unless you have a pacemaker</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are suffering from heart failure (with a reduced ejection fraction of less than 35% and/or pulmonary wedge pressure of more than 20&nbsp;mmHg) (provided that this is not due to supraventricular tachycardia, which responds to verapamil)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are suffering from atrial fibrillation/flutter (abnormal heartbeat following increased pathogenic stimulation of the atrium), and, at the same time, WPW (intermittent accelerated heartbeat resulting from accelerated conduction between the atria and the ventricles via an accessory conduction pathway) or Lown-Ganong-Levine syndrome: You are at greater risk of developing rapid ventricular heartbeat (ventricular tachycardia) including ventricular fibrillation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are already taking medication containing ivabradine for the treatment of certain heart conditions.</p><p>&nbsp;</p><p>Beta receptor blockers should not be administered intravenously at the same time as this medicine (except in intensive care medicine).</p><p><strong>Particular caution must be exercised when taking Isoptin 80 mg</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have recently suffered a heart attack with complications, e.g. slow heartbeat (bradycardia), marked drop in blood pressure (hypotension) or left-sided heart failure (left cardiac insufficiency)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience mild cardiac conduction disorders between the atrium and the ventricles (first degree AV block)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have low blood pressure (systolic pressure below 90&nbsp;mmHg)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a resting pulse below 50 beats per minute (bradycardia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have seriously impaired liver function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are suffering from neuromuscular transmission disorders (such as <em>Myasthenia gravis</em>, Lambert-Eaton syndrome, progressive Duchenne muscular dystrophy)</p><p>As comparative studies have reliably shown, impaired renal function in patients with end- stage kidney failure has no effect on the pharmacokinetics of verapamil, i.e. the processes to which verapamil is exposed in the body. Nevertheless, individual case reports suggest that verapamil should only be used with caution and strict monitoring in patients with impaired kidney function. Verapamil cannot be removed by haemodialysis.</p><p>Regular medical monitoring is essential when this medicine is being used to treat high blood pressure.</p><p>&nbsp;</p><p><strong>Other medicines and Isoptin 80 mg:</strong></p><p>Tell your doctor or pharmacist if you are taking/using, have recently taken/used or might take/use any other medicines.</p><p>The effect of the following active substances or groups of preparations may be affected if administered at the same time as this medicine:</p><p><strong>Anti-arrhythmics (e.g. flecainide, disopyramide), beta-receptor blockers (e.g. metoprolol, propranolol), inhalation anaesthetics:</strong></p><p>Mutual potentiation of cardiovascular effects (severe AV block, severe drop in heart rate, onset of heart failure, substantial fall in blood pressure).</p><p>Beta receptor blockers must not be administered intravenously to patients at the same time as this medicine (except in intensive care medicine).</p><p><strong>Antihypertensives (to lower the blood pressure), diuretics (to promote urine production) and vasodilators (to dilate the vessels):</strong></p><p>Increased antihypertensive effect.</p><p><strong>Digoxin, digitoxin (active substances to stimulate the heart):</strong></p><p>Increase in digoxin or digitoxin concentration in the blood due to reduced elimination via the kidneys. Particular attention should therefore be paid to signs of an overdose with these active substances. If necessary, the dose should be reduced by a doctor (possibly after determining the concentration in the blood).</p><p><strong>Quinidine (active substance to stop irregular heartbeat):</strong></p><p>A marked fall in blood pressure may occur; patients with a certain heart condition (hypertrophic obstructive cardiomyopathy) may develop pulmonary oedema (abnormal accumulation of fluid in the lungs); increased concentration of quinidine in the blood.</p><p><strong>Carbamazepine (active substance to treat epileptic seizures):</strong></p><p>The effect of carbamazepine is intensified. Increase in nerve-damaging side effects.</p><p>The verapamil hydrochloride concentration in the blood is lowered. The effect of verapamil hydrochloride is reduced.</p><p><strong>Lithium (active substance to treat depression):</strong></p><p>The effect of lithium is reduced. Increase in nerve-damaging side effects.</p><p><strong>Muscle relaxants (medication to relax the muscles):</strong></p><p>Potential increased effect due to this medicine.</p><p><strong>Acetylsalicylic acid (active substance to treat pain and prevent blood clots):</strong></p><p>Increased tendency to bleed.</p><p><strong>Doxorubicin (active substance to treat tumours):</strong></p><p>If doxorubicin and verapamil are administered orally at the same time, the concentration of doxorubicin in the blood (bioavailability and peak plasma levels) is increased in patients with small-cell lung carcinoma. No significant changes in the pharmacokinetic profile of doxorubicin have been observed in patients with advanced tumours following concomitant intravenous administration of verapamil.</p><p><strong>Colchicine (active substance for the treatment of gout):</strong></p><p>Colchicine plasma levels may be increased if verapamil and colchicine are administered at the same time.</p><p><strong>Dabigatran (active substance to inhibit blood coagulation): and other direct oral anticoagulants (DOACs):</strong></p><p>When administered at the same time as verapamil, the plasma level of the anticoagulant can be increased. This may require the dosage of the anticoagulant to be adjusted (see dosage information in the package insert for the anticoagulant).</p><p><strong>Ethanol (alcohol):</strong></p><p>Delay in the breakdown of ethanol, an increase in ethanol concentrations in the blood, and therefore an increased effect of alcohol due to this medicine.</p><p><strong>Fungistatic agents (active substances for the treatment of fungal diseases, such as clotrimazole, ketoconazole or itraconazole), protease inhibitors (active substances for the treatment of HIV, such as ritonavir or indinavir), active substances to treat infections (macrolides, such as erythromycin, clarithromycin, telithromycin), cimetidine (active substance to reduce gastric acid production), almotriptan (active substance to treat migraine), imipramine (active substance to treat depression), glibenclamide (active substance to treat diabetes), benzodiazepines and other anxiolytics (medication to treat psychological disorders, such as buspirone and midazolam):</strong></p><p>Increase in the verapamil hydrochloride concentration and/or the concentration of these medicines in the blood due to (mutual) impact on degradation.</p><p>Verapamil can reduce the blood sugar lowering effects of metformin.</p><p><strong>Phenytoin, phenobarbital, rifampicin (active substance for the treatment of tuberculosis), medication to increase the elimination of uric acid (uricosuric medicines, e.g. sulfinpyrazone), St. John&rsquo;s Wort preparations:</strong></p><p>Decrease in the verapamil hydrochloride concentration in the blood and reduced effect of verapamil hydrochloride.</p><p><strong>Anti-arrhythmics (medication to treat irregular heartbeat, such as amiodarone), cyclosporine, everolimus, sirolimus, tacrolimus (immunosupressants &ndash; to reduce the activity of the immune system), theophylline (active substance to treat asthma), prazosin (active substance to treat high blood pressure), terazosin (active substance to treat urination problems in the case of an enlarged prostate):</strong></p><p>Increase in the concentrations of these medicines in the blood.</p><p><strong>HMG-CoA reductase inhibitors (&ldquo;statins&rdquo;; medication to lower high blood lipid levels):</strong></p><p>Simultaneous administration of verapamil and HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin or lovastatin) can increase the concentration of these medicines in the blood.</p><p>Patients taking verapamil should therefore start treatment with an HMG-CoA reductase inhibitor (e.g. simvastatin, atorvastatin or lovastatin) at the lowest possible dose and be up-titrated (dose increased gradually). If verapamil treatment is added to existing HMG-CoA reductase inhibitor therapy (e.g. simvastatin, atorvastatin or lovastatin), a reduction in the statin dose should be considered with back-titration (decrease) against the serum-cholesterol concentration. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>When high doses of verapamil and simvastatin are taken at the same time, the risk of skeletal muscle disorder (myopathy) or destruction of muscle cells (rhabdomyolysis) is increased. The simvastatin dose should be adjusted as directed by the manufacturer.</p><p>Fluvastatin, pravastatin and rosuvastatin are not metabolised through cytochrome P450 isoenzyme 3A4. An interaction with verapamil is less likely.</p><p>This medicine should not be administered with one of the afore-mentioned medicines or active substances unless expressly indicated by your doctor.</p><p>&nbsp;</p><p><strong>Isoptin 80 mg with food, drink and alcohol</strong></p><p>If possible, do not drink any <strong>alcohol </strong>whilst taking this medicine, since the effect of the alcohol will be increased by this medicine. You should not consume any food or drinks containing grapefruit whilst taking this medicine.<strong>Grapefruit</strong> can increase the concentration of verapamil hydrochloride in the blood.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong> Pregnancy</strong></p><p>Verapamil hydrochloride, the active substance contained in this medicine, can cross the placenta. There is insufficient experience regarding the use of verapamil hydrochloride during pregnancy. However, data on a limited number of orally treated pregnant women does not suggest that verapamil hydrochloride has teratogenic effects. Animal studies have shown that this medicine can have harmful effects on the young. Therefore, you should not take this medicine in the first six months of pregnancy. During the last three months of pregnancy, you should only take this medicine if your doctor considers this to be essential, taking into account the risk to mother and child.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Breast-feeding</strong></p><p>Verapamil passes into the breast milk. Limited human data following oral administration has shown that the nursing infant absorbs only a small quantity of the active substance (0.1 to 1% of the maternal dose). Verapamil can therefore be considered compatible with breast-feeding.</p><p>A risk to new-born/nursing infants cannot be ruled out. However, due to the risk of severe side effects in the nursing infant, verapamil should only be used during breastfeeding if this is absolutely necessary for the wellbeing of the mother.</p><p>There is evidence that, in individual cases, verapamil hydrochloride can cause an increase in prolactin secretion and trigger spontaneous lactation.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Even if taken as directed, this medicine can alter the reaction capacity to such an extent that the ability to drive, use machines or work with unsafe footing may be adversely affected. This is particularly evident at the start of treatment, if the dose is increased or the preparation changed, or when additional medication is initially taken, and in conjunction with alcohol. This medicine can increase alcohol levels in the blood and delay its elimination, as a result of which the effects of alcohol may be enhanced.</p><p><strong>Isoptin 80 mg contains sodium </strong></p><p>This medicinal product contains less than 1 mmol (23 mg) sodium per film-coated tablet, that is to say essentially &#39;sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Verapamil hydrochloride, the active substance contained in this medicine, should be dosed on an individual basis, depending on the severity of the patient&rsquo;s condition. Long-standing clinical experience shows that the average dose in all indications is between 240&nbsp;mg and 360&nbsp;mg per day.</p><p>A daily dose of 480&nbsp;mg should not be exceeded as long-term therapy. It may be increased for a short period.</p><p>The recommended dose is:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Use in adults and adolescents weighing over 50&nbsp;kg:</strong></p><p><strong>Symptoms in situations involving an inadequate supply of oxygen to the cardiac muscles (angina pectoris)</strong></p><p>The recommended dose is 240&nbsp;mg &ndash; 480&nbsp;mg verapamil hydrochloride per day in 3 to 4 single doses, equivalent to:</p><p>1 film-coated tablet of this medicine 3 to 4 times a day (equivalent to 240 mg &ndash; 320 mg verapamil hydrochloride per day).</p><p>Pharmaceutical forms with appropriate strengths are available if higher doses (e.g. 360 mg &ndash; 480 mg verapamil hydrochloride per day) are required.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>High blood pressure</strong></p><p>The recommended dose is 240&nbsp;mg &ndash; 360 mg verapamil hydrochloride per day in 3 single doses, equivalent to:</p><p>1 film-coated tablet of this medicine 3 times a day (equivalent to 240 mg verapamil hydrochloride per day).</p><p>Pharmaceutical forms with appropriate strengths are available if higher doses (e.g. 360 mg verapamil hydrochloride per day) are required.</p><p><strong>Irregular heartbeat (paroxysmal supraventricular tachycardia, atrial fibrillation / atrial flutter with rapid AV conduction [except in WPW syndrome])</strong></p><p>The recommended dose is 240&nbsp;mg &ndash; 480&nbsp;mg verapamil hydrochloride per day in 3 to 4 single doses, equivalent to:</p><p>1 film-coated tablet of this medicine 3 to 4 times a day (equivalent to 240 mg &ndash; 320 mg verapamil hydrochloride per day).</p><p>Pharmaceutical forms with appropriate strengths are available if higher doses (e.g. 360 mg &ndash; 480 mg verapamil hydrochloride per day) are required.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;<strong>Children (for irregular heartbeat only):</strong></p><p><strong>&nbsp;</strong></p><p><strong>Older pre-school children up to 6 years of age:</strong></p><p>The recommended dose is 80 mg &ndash; 120 mg verapamil hydrochloride per day in 2 to 3</p><p>&nbsp;single doses:</p><p>Pharmaceutical forms with appropriate strengths (40 mg verapamil hydrochloride) are available for this purpose.</p><p>&nbsp;</p><p><strong>School children 6 &ndash; 14 years of age:</strong></p><p>The recommended dose is 80 mg to 360 mg verapamil hydrochloride per day in 2 to 4</p><p>&nbsp;single doses, equivalent to:</p><p>1 to 2 film-coated tablet(s) of this medicine 2 to 4 times a day (equivalent to 160 mg &ndash; 320 mg verapamil hydrochloride per day).</p><p>This medicine is used provided that no adequate effect is achieved with lower doses (e.g. 80 mg verapamil hydrochloride per day).</p><p>Pharmaceutical forms with appropriate strengths are available if higher doses (e.g. 360 mg verapamil hydrochloride per day) are required.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Impaired kidney function</strong><br />The information currently available is described in section 2. This medicine should be administered with caution and under strict monitoring to patients with impaired kidney function.</p><p>&nbsp;</p><p>&middot;&nbsp; &nbsp; &nbsp;Impaired liver function</p><p>The effect of verapamil hydrochloride is increased and prolonged in patients with impaired liver function, depending on the severity, because of the medicine&rsquo;s delayed metabolism. In such cases, the dose should therefore be carefully adjusted accordingly by a doctor, starting with low doses (e.g. in patients with impaired liver function, initially 40&nbsp;mg verapamil hydrochloride 2 to 3 times daily, equivalent to 80&nbsp;mg &ndash; 120&nbsp;mg verapamil hydrochloride per day) (see also section 2).</p><p><u>Method of administration </u></p><p>For oral use.</p><p>Please take this medicine <strong>whole </strong>and <strong>unchewed </strong>with sufficient liquid (e.g. a glass of water, no grapefruit juice), preferably with or shortly after food.</p><p><strong>Do not take </strong>this medicine <strong>when lying down</strong>.</p><p>If this medicine has been prescribed for you to treat pain and a tight chest (angina pectoris) following a heart attack, do not take it until 7 days after the heart attack.</p><p><u>Duration of administration </u></p><p>The duration of administration is not limited. It will be set by the doctor who is treating you.</p><p>Please speak to your doctor or pharmacist if you feel that the effects of this medicine are too strong or too weak.</p><p><strong>If you take more Isoptin 80 mg than you should</strong></p><p>The following clinical signs and symptoms may appear if you have unintentionally or deliberately taken too much of this medicine:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious drop in blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular heartbeat (e.g. delayed or accelerated heartbeat, cardiac conduction disorders), which may lead to cardiovascular shock and cardiac arrest</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of consciousness, possibly culminating in coma</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in blood glucose levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lowering of blood potassium levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in pH of the blood (metabolic acidosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lack of oxygen in the body tissue (hypoxia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiovascular shock with an accumulation of water in the lungs (pulmonary oedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impaired kidney function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Spasms.</p><p>&nbsp;</p><p>Deaths have occasionally been reported.</p><p>If any of the afore-mentioned symptoms appear, contact a doctor/emergency doctor immediately. He/she will take the necessary action.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Isoptin 80 mg</strong></p><p>Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking Isoptin 80 mg</strong></p><p>Please do not interrupt or discontinue treatment with this medicine without discussing this in advance with your doctor.</p><p>This medicine should not be stopped suddenly after long-term treatment, but discontinued gradually.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everyone gets them.</p><p>The following categories are used to establish the frequency of side effects:</p><p>Very common:&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; can affect more than 1 in 10 patients</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; can affect up to 1 to 10 patients</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; can affect up to 1 in 100 patients</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; can affect up to 1 in 1000 patients</p><p>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; can affect up to 1 in 10,000 patients</p><p>Unknown:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; frequency cannot be estimated based on the available data</p><p><strong>&nbsp;</strong></p><p><strong>Common side effects</strong> (can affect up to 1 in 10 patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness or giddiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headaches</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neuropathy (nervous system disorders)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slowed heartbeat (bradycardia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Onset of heart failure or deterioration of pre-existing heart failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive drop in blood pressure and/or disorders caused by drop in blood pressure when changing the body position from lying or sitting to standing (orthostatic dysregulation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushes (reddening of the face with sensation of warmth)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension (low blood pressure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painful redness and swelling of the limbs (erythromelalgia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ankle oedema (peripheral oedema)</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(can affect up to 1 in 100 patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced glucose tolerance</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapid heartbeat (tachycardia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Probably allergy-induced inflammation of the liver (hepatitis) with an increase in liver-specific enzymes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue</p><p>&nbsp;</p><p><strong>Rare side effects </strong>(can affect up to 1 in 1000 patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal sensations such as tingling, numbness or cold sensation in the limbs (paraesthesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drowsiness/dizziness/disorientation (somnolence)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ringing in the ears (tinnitus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased sweating (hyperhidrosis)</p><p>&nbsp;</p><p><strong>Very rare side effects </strong>(can affect up to 1 in 10,000 patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin reactions similar to sunburn (photodermatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Worsening of certain muscle disorders (<em>Myasthenia gravis</em>, Lambert-Eaton syndrome, advanced Duchenne muscular dystrophy)</p><p>&nbsp;</p><p><strong>The following side effects have occurred with a frequency which could not be estimated on the basis of the available data</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal involuntary movements (extrapyramidal symptoms)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paralysis (tetraparesis)<br />(There has been one isolated post-marketing report of paralysis, specifically of weakness in the arms and legs (tetraparesis) in connection with the concomitant administration of verapamil hydrochloride (active substance contained in this medicine) and colchicine (active substance for the treatment of gout))</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Spasms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive blood potassium concentrations (hyperkalaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness (vertigo)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious cardiac conduction disorders [AV block (1<sup>st</sup> , 2<sup>nd</sup> and 3<sup>rd</sup> degree)]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart failure (cardiac insufficiency)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sinus arrest</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sinus bradycardia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiac arrest (asystole)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bronchial smooth muscle spasm (bronchospasm)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath (dyspnoea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Overgrowth of gum tissue (gingival hyperplasia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intestinal obstruction (ileus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swollen tissue, especially in the face (angioedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic skin reaction with serious impact on general condition (Stevens-Johnson syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erythema multiforme</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss (alopecia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching (pruritus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Spots or patches on the skin or mucosa due to bleeding (purpura)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash with spots and bumps on the surface of the skin (maculopapular exanthema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nettle rash (urticaria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain (arthralgia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscular weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscular pain (myalgia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impotence (erectile dysfunction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milky discharge (galactorrhoea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enlargement of male breast tissue (gynaecomastia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased prolactin values in the blood</p><p><strong>Note</strong></p><p>An adverse effect on pacemaker function during verapamil hydrochloride therapy cannot be ruled out in patients fitted with pacemakers.</p><p><strong>Countermeasures</strong></p><p>If you notice any of the afore-mentioned side effects, inform your doctor so that he/she can decide on the severity and take any other action that may be required.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the</p><p><strong>To report any side effect(s):</strong></p><p><strong>-National Pharmacovigilance Center (NPC)</strong></p><p><strong>o Fax: +966-11-205-7662</strong></p><p><strong>o SFDA Call Center: 19999</strong></p><p>o <strong>E-mail: npc.drug@sfda.gov.sa</strong></p><p>o <strong>Website: https://ade.sfda.gov.sa</strong></p><p>By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store over 30&deg;C</p><p><strong>Shelf life: </strong>36 months</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister strips after &ldquo;Use by&rdquo;. The expiry date refers to the last day of that month.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The <strong>active substance</strong> is verapamil hydrochloride.</p><p>1 film-coated tablet contains 80&nbsp;mg verapamil hydrochloride.</p><p>The <strong>other</strong> <strong>ingredients</strong> are:<br />Calcium hydrogen phosphate dihydrate, croscarmellose sodium, highly dispersed silicon dioxide, hypromellose, macrogol 6000, magnesium stearate (Ph.Eur.), microcrystalline cellulose, sodium dodecyl sulphate, talcum, titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                White, biconvex, film-coated tablets debossed with “Isoptin 80” on the upper side and “Knoll” on the underside followed by a break-line.

This medicine is available in the following pack sizes:
Original pack containing 	20 film-coated tablets
Original pack containing 	50 film-coated tablets 
Original pack containing 	100 film-coated tablets
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder:</p><p>Abbott Laboratories GmbH,</p><p>Hannover, Germany</p><p>&nbsp;</p><p>Manufacturer</p><p>FAMAR A.V.E. Anthoussa</p><p>7, Anthoussa Avenue &nbsp;153 44</p><p>Anthoussa, Athens</p><p>Greece</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                07/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يستخدم هذا الدواء لعلاج أمراض القلب المرتبطة بنقص إمدادات الأكسجين إلى عضلة القلب، وكذلك علاج اضطرابات معينة بضربات القلب (عدم انتظام ضربات القلب)، وعلاج ارتفاع ضغط الدم.</p><p>&nbsp;</p><p>ي<strong>ستخدم إيزوبتين 80 ملجم من أجل:</strong></p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp; الاضطرابات (على سبيل المثال، ألم أو إحساس بضيق في منطقة الصدر) في الحالات التي تنطوي على نقص وصول الأوكسجين إلى عضلة القلب (ذبحة صدرية):</li></ul><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند المجهود: الذبحة الصدرية المستقرة المزمنة (الذبحة التي تحدث عند بذل المجهود)</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند الراحة: ذبحة صدرية غير مستقرة (الذبحة الصدرية المتصاعدة، والذبحة التي تحدث عند الراحة)</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضيق الأوعية الدموية: الذبحة الصدرية الوعائية التشنجية (ذبحة برنزميتال الصدرية، الذبحة الصدرية المتغيرة)</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذبحة الصدرية بعد أزمة قلبية في المرضى الذين لا يعانون من فشل بالقلب عندما لا يوجد داعٍ لتلقي العلاج بحاصرات بيتا.</p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp; &nbsp;عدم انتظام ضربات القلب بما في ذلك:</li></ul><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات سرعة ضربات القلب التي تبدأ فوق البطينين (تسارع القلب الانتيابي فوق البطيني)</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجفان الأذيني/الرفرفة الأذينية (ضربات قلب غير طبيعية بعد زيادة التنبيه المرَضي للأذين) مع توصيل أذيني بطيني سريع [إلا في متلازمة وولف-باركنسون-وايت (WPW) أو متلازمة لون- جانونج- ليفين]</p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp; &nbsp;ارتفاع ضغط الدم</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>تجنب استخدام إيزوبتين 80 ملجم في الحالات التالية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;إذا كنت مصابًا بالحساسية تجاه هيدروكلوريد الفيراباميل أو أي مكون آخر من مكونات هذا الدواء والمدرجة في القسم 6</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن أصبت من قبل بصدمة قلبية وعائية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا باضطرابات شديدة بالتوصيل القلبي بين العقدة الجيبية والأذين [الإحصار الجيبي الأذيني من الدرجة الثانية والثالثة]، ما لم يكن لديك منظم لنبض القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا باضطرابات شديدة بالتوصيل القلبي بين الأذين والبطينين [الإحصار الأذيني البطيني من الدرجة الثانية والثالثة]، ما لم يكن لديك منظم لنبض القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من متلازمة العقدة الجيبية المريضة (عدم انتظام ضربات القلب بعد خلل بوظيفة العقدة الجيبية)، مثل انخفاض معدل ضربات القلب إلى أقل من 60 نبضة في الدقيقة أو ضربات القلب الانتيابية المتأخرة أو المتسارعة أو اضطرابات التوصيل القلبي بين العقدة الجيبية والأذين أو نقص تنبيه العقدة الجيبية (تباطؤ القلب الجيبي أو متلازمة تسارع القلب-تباطؤ القلب أو الإحصار الجيبي الأذيني أو السكتة الجيبية) ما لم يكن لديك منظم لنبض القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من فشل القلب (مع نقص الكسر القذفي بأقل من 35% و/أو زيادة الضغط الإسفيني الرئوي بأكثر من 20 مم زئبقي) (بشرط ألا يكون سبب ذلك هو تسرع القلب فوق البطيني، الذي يستجيب لفيراباميل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من رجفان أذيني/رفرفة أذينية (ضربات القلب غير الطبيعية بعد زيادة التنبيه المرضي للأذين)، وفي نفس الوقت متلازمة وولف باركنسون وايت (التسارع الانتيابي لضربات القلب بسبب تسارع التوصيل بين الأذينين والبطينين عن طريق مسار توصيل إضافي) أو متلازمة لون جانونج ليفين. إن كنت أكثر عرضة لخطر الإصابة بسرعة ضربات القلب البطينية (تسارع القلب البطيني) بما في ذلك الرجفان البطيني</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تتناول بالفعل أدوية تحتوي على ايفابرادين لعلاج بعض حالات القلب.</p><p dir="RTL">ويجب عدم إعطاء المريض حاصرات مستقبلات بيتا عن طريق الوريد في ذات الوقت الذي يُعطى فيه هذا الدواء (إلا في حالة العلاج في إطار طب العناية المركزة).</p><p><strong>يجب اتخاذ الحذر بصفة خاصة عند تناول إيزوبتين 80 ملجم</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت قد أصبت مؤخرًا بأزمة قلبية مصحوبة بمضاعفات، مثل بطء ضربات القلب (تباطؤ القلب)، أو الهبوط اللافت لضغط الدم (انخفاض ضغط الدم)، أو فشل الجانب الأيسر للقلب (قصور الجانب الأيسر للقلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن أصبت باضطرابات خفيفة بالتوصيل القلبي بين الأذين والبطينين (إحصار أذيني بطيني من الدرجة الأولى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن أصبت بانخفاض ضغط الدم (ضغط الدم الانقباضي أقل من 90 مم زئبقي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كان معدل نبض القلب في وقت الراحة أقل من 50 نبضة في الدقيقة (تباطؤ القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا بقصور خطير بالكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني اضطرابات البث العصبي العضلي (مثل <em>الوهن العضلي الوبيل</em>، أو متلازمة لامبرت-إيتون، أو الحثل العضلي الدوشيني المتزايد).</p><p dir="RTL">وكما أظهرت دراسات مقارَنة موثوقة، فإن قصور وظيفة الكلى لدى المرضى بالمرحلة النهائية من الفشل الكلوي ليس له تأثير على الحرائك الدوائية لفيراباميل، أي على العمليات التي يتعرض لها فيراباميل في الجسم. ولكن تقارير الحالات الفردية تشير إلى أن فيراباميل ينبغي ألا يستخدم إلا بحذر وتحت المراقبة الصارمة في المرضى المصابين بقصور وظيفة الكلى. ولا يمكن إزالة فيراباميل عن طريق الغسيل الكلوي.</p><p dir="RTL">المراقبة الطبية المنتظمة ضرورية عند استخدام الدواء لعلاج ضغط الدم المرتفع.</p><p>&nbsp;</p><p><strong>الأدوية الأخرى وإيزوبتين 80 ملجم:</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول/تستخدم حاليًا أي أدوية أخرى، أو تناولتها/استخدمتها مؤخرًا أو قد تتناولها/تستخدمها مستقبلاً.</p><p dir="RTL">قد تتأثر فعالية المواد النشطة أو مجموعات المستحضرات التالية في حالة إعطائها في نفس الوقت مع هذا الدواء:</p><p><strong>مضادات اضطراب نظم القلب (مثل فليكانيد، وديسوبيراميد)، وحاصرات مستقبلات بيتا (مثل ميتوبرولول، وبروبرانولول)، وأدوية التخدير المستنشقة:</strong></p><p dir="RTL">الزيادة المتبادلة للتأثيرات القلبية الوعائية (إحصار العقدة الأذينية البطينية الحاد، والانخفاض الشديد في معدل ضربات القلب، والإصابة بقصور قلبي، والهبوط الكبير بضغط الدم).</p><p dir="RTL">ويجب عدم إعطاء المريض حاصرات مستقبلات بيتا عن طريق الوريد للمرضى في ذات الوقت الذي يُعطى فيه هذا الدواء (إلا في سياق طب العناية المركزة).</p><p><strong>الأدوية المضادة لارتفاع ضغط الدم (لخفض ضغط الدم) ومدرات البول (لتحفيز إنتاج البول) وموَسعات الأوعية الدموية (لتوسيع الأوعية الدموية):</strong></p><p dir="RTL">زيادة الأثر المضاد لارتفاع ضغط الدم.</p><p><strong>ديجوكسين وديجيتوكس (مواد فعالة لتحفيز القلب):</strong></p><p dir="RTL">ارتفاع تركيز ديجوكسين وديجيتوكس في الدم بسبب انخفاض الإخراج عن طريق الكليتين. ينبغي الانتباه بصفة خاصة لعلامات فرط الجرعة مع تلك المواد الفعالة. وعند اللزوم، ينبغي خفض الجرعة بواسطة الطبيب (ويحتمل أن يكون ذلك بعد تحديد التركيز في الدم).</p><p><strong>كينيدين (مادة فعالة لإيقاف عدم انتظام ضربات القلب):</strong></p><p dir="RTL">قد يحدث هبوط لافت بضغط الدم؛ وقد يصاب المرضى الذين يعانون من حالة معينة بالقلب (اعتلال عضلة القلب الضخامي الانسدادي) بوذمة رئوية (تراكم غير طبيعي من السوائل في الرئتين)، وقد تحدث زيادة بتركيز الكينيدين في الدم.</p><p><strong>كاربامازيبين (مادة فعالة تستخدم لعلاج نوبات الصرع):</strong></p><p dir="RTL">يشتد تأثير كاربامازيبين. تزداد الآثار الجانبية المتلفة للأعصاب.</p><p dir="RTL">ينخفض تركيز هيدروكلوريد الفيراباميل في الدم. يقل تأثير هيدروكلوريد الفيراباميل.</p><p><strong>الليثيوم (مادة فعالة لعلاج الاكتئاب):</strong></p><p dir="RTL">يقل تأثير الليثيوم. تزداد الآثار الجانبية المتلفة للأعصاب.</p><p><strong>مُرخيات العضلات (الأدوية التي تعمل على إرخاء العضلات):</strong></p><p dir="RTL">يحتمل أن يزيد أثرها بسبب هذا الدواء.</p><p><strong>حمض الأسيتيل ساليسيليك (مادة فعالة لعلاج الألم والوقاية من الجلطات الدموية):</strong></p><p dir="RTL">تزداد احتمالية حدوث نزيف مع حمض الأسيتيل ساليسيليك.</p><p><strong>دوكسوروبيسين (مادة فعالة لعلاج الأورام):</strong></p><p dir="RTL">في حالة إعطاء دوكسوروبيسين وفيراباميل بالفم في نفس الوفت، يزداد تركيز دوكسوروبيسين في الدم (الإتاحة الحيوية والمستويات القصوى في البلازما) في المرضى الذين يعانون من سرطان الخلايا الصغيرة بالرئة. لم تُلاحظ تغيرات لافتة في حالة الحرائك الهوائية لدوكسوروبيسين في المرضى بالأورام المتقدمة بعد الإعطاء الوريدي بالتزامن مع فيراباميل.</p><p><strong>الكولشيسين (المادة الفعالة لعلاج النقرس):</strong></p><p dir="RTL">قد تزداد مستويات الكولشيسين في البلازما في حالة إعطاء فيراباميل والكولشيسين في نفس الوقت.</p><p><strong>دابيجاتران (المادة الفعالة لتثبيط تخثر الدم): ومضادات التجلط الفموية المباشرة الأخرى (DOACs):</strong></p><p>عند إعطاء ذلك في نفس الوقت مع فيراباميل، فيمكن أن يزيد مستوى مضاد التجلط بالبلازما. وقد يتطلب ذلك ضبط جرعة مضاد التجلط (انظر معلومات الجرعة في النشرة المرفقة بعبوة مضاد التجلط).</p><p><strong>الإيثانول (الكحول):</strong></p><p dir="RTL">تأخر انحلال الإيثانول، وزيادة تركيزات الإيثانول في الدم، مما يؤدي بدوره إلى زيادة أثر الكحول بسبب هذا الدواء.</p><p><strong>العقاقير الكابحة للفطريات (المواد الفعالة لعلاج الأمراض الفطرية، مثل كلوتريمازول أو كيتوكونازول أو إتراكونازول)، ومثبطات البروتياز (المواد الفعالة لعلاج فيروس نقص المناعة البشرية، مثل ريتونافير أو إندينافير)، والمواد الفعالة لعلاج العدوى (أدوية الماكروليد، مثل إريثرومايسين وكلاريثرومايسين وتيليثرومايسين)، وسيميتيدين (المادة الفعالة للحد من إنتاج حامض المعدة) وألموتريبتان (المادة الفعالة لعلاج الصداع النصفي)، وإيميبرامين (المادة الفعالة لعلاج الاكتئاب)، وجليبينكلاميد (المادة الفعالة لعلاج السكري)، وأدوية البنزوديازيبين وغيرها من مضادات القلب (دواء لعلاج الاضطرابات النفسية، مثل بوسبيرون وميدازولام):</strong></p><p dir="RTL">زيادة تركيز هيدروكلوريد الفيراباميل و/أو تركيز تلك الأدوية في الدم بسبب الأثر (المشترك) على الانحلال.</p><p dir="RTL">يمكن أن يقلل فيراباميل من تأثيرات خفض نسبة السكر في الدم للمتفورمين.</p><p><strong>الفينيتوين، الفينوباربيتال، ريفامبيسين (المادة الفعالة لعلاج السل)، دواء لزيادة إخراج حمض اليوريك (الأدوية المحفزة لبيلة حمض اليوريك، على سبيل المثال سلفينبيرازون)، ومستحضرات عشبة القديس يوحنا:</strong></p><p dir="RTL">نقص تركيز هيدروكلوريد الفيراباميل في الدم، والحد من تأثير هيدروكلوريد الفيراباميل.</p><p><strong>مضادات اضطراب نبض القلب (أدوية لعلاج ضربات القلب غير المنتظمة، مثل أميودارون) وسيكلوسبورين وإيفيروليموس وسيروليموس وتاكروليموس (مثبطات للمناعة - للحد من نشاط الجهاز المناعي) وثيوفيللين (المادة الفعالة لعلاج الربو) وبرازوسين (المادة الفعالة لعلاج ضغط الدم المرتفع وتيرازوسين (المادة الفعالة لعلاج مشكلات التبول في حالة تضخم البروستاتا):</strong></p><p dir="RTL">زيادة تركيزات هذه الأدوية في الدم.</p><p><strong>مثبطات مختزلة الإنزيم HMG-CoA (&quot;الستاتينات&quot;، وهي أدوية لخفض مستويات الدهون في الدم):</strong></p><p dir="RTL">يمكن أن يؤدي إعطاء فيراباميل بالتزامن مع مثبطات مختزلة الإنزيم HMG-CoA (مثل سيمفاستاتين أو أتورفاستاتين أو لوفاستاتين) إلى زيادة تركيز تلك الأدوية في الدم.</p><p dir="RTL">لذلك على المرضى الذين يتناولون فيراباميل بدء العلاج بمثبطات مختزلة الإنزيم HMG-CoA (مثل سيمفاستاتين، أو أتورفاستاتين أو لوفاستاتين) بأقل جرعة ممكنة مع التدرج لأعلى في معايرتها (زيادة جرعتها بالتدريج). عند إضافة العلاج بالفيراباميل إلى العلاج الحالي بمثبطات مختزلة الإنزيم HMG-CoA (مثل سيمفاستاتين أو أتورفاستاتين أو لوفاستاتين)، فيجب دراسة تقليل جرعة ستاتين ويجب إجراء معايرة رجعية (خفض الجرعة) وفق تركيز الكوليسترول في مصل الدم.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">عند إعطاء جرعات عالية من فيراباميل وسيمفاستاتين في نفس الوقت، يزداد خطر اضطراب العضلات الهيكلية (الاعتلال العضلي) أو تدمير الخلايا العضلية (انحلال الربيدات). ينبغي ضبط جرعة سيمفاستاتين حسب توجيهات الشركة المصنّعة.</p><p dir="RTL">لا يتم استقلاب فلوفاستاتين، وبرافاستاتين وروسوفاستاتين عن طريق النظير الإنزيمي 3A4 للسيتوكروم البشري P450. وتوجد احتمالية منخفضة لحدوث تفاعل مع الفيراباميل.</p><p dir="RTL">لا ينبغي إعطاء هذا الدواء مع أحد الأدوية أو المواد الفعالة التي سبق ذكرها ما لم يوصِ بذلك طبيبك صراحةً.</p><p>&nbsp;</p><p><strong>استخدام إيزوبتين 80 ملجم مع الطعام والشراب والكحول</strong></p><p dir="RTL">إن أمكن، فلا تتناول أي مشروبات <strong>كحولية </strong>أثناء فترة استخدامك هذا الدواء، لأن أثر الكحول سيزداد بسبب هذا الدواء. ينبغي ألا تتناول أي أطعمة أو مشروبات تحتوي على الجريب فروت أثناء فترة استخدامك هذا الدواء.<strong>الجريب فروت</strong> يمكن أن تزيد من تركيز هيدروكلوريد الفيراباميل في الدم.</p><p>&nbsp;</p><p><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">إذا كانت المريضة حاملاً أو ترضع رضاعة طبيعية أو تعتقد أنها ربما تكون حاملاً أو تخطط للحمل، فيُرجى استشارة الطبيب أو الصيدلاني قبل تناول هذا الدواء.</p><p dir="RTL"><strong>&middot;&nbsp;الحمل</strong></p><p dir="RTL">يمكن لهيدروكلوريد الفيراباميل، وهو المادة الفعالة في هذا الدواء، أن يعبر المشيمة. لا توجد خبرة كافية بشأن استخدام هيدروكلوريد الفيراباميل خلال فترة الحمل. ومع ذلك، فإن البيانات المتعلقة بعدد محدود من النساء الحوامل اللاتي تم علاجهن عن طريق الفم لا تشير إلى أي تأثير مسبب للتشوهات لهيدروكلوريد الفيراباميل. أظهرت الدراسات على الحيوانات أن هذا الدواء يمكن أن تكون له آثار ضارة على صغارها. ولذلك، ينبغي ألا تتناولي هذا الدواء في أول ستة أشهر من الحمل. أثناء الشهور الثلاثة الأخيرة من الحمل، ينبغي ألا تتناولي هذا الدواء إلا إذا كان طبيبك يرى ذلك ضروريًا، مع مراعاة الخطر الذي تتعرض له الأم وطفلها.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;<strong>الرضاعة الطبيعية</strong></p><p dir="RTL">دواء فيراباميل من الأدوية التي تتسرب إلى حليب الأم. أظهرت البيانات المحدودة بعد إعطاء الدواء للبشر بالفم إن الأطفال الرُضع لا يمتصون سوى كمية صغيرة من المادة الفعالة (0.1 إلى 1% من جرعة الأم). لذلك يمكن اعتبار فيراباميل متوافقًا مع الرضاعة الطبيعية.</p><p dir="RTL">ولا يمكن استبعاد المخاطر الواقعة على الأطفال حديثي الولادة/الرضع. ومع ذلك، وبسبب مخاطر التأثيرات الجانبية الحادة لدى الأطفال الرضع، فإنه يجب استخدام فيراباميل أثناء الرضاعة الطبيعية فقط إذا كان ذلك ضروريًا لصحة الأم بشكل قاطع.</p><p dir="RTL">توجد أدلة على أن هيدروكلوريد الفيراباميل يمكن أن يسبب زيادة بتركيز البرولاكتين في حالات فردية، كما قد يحفز إدرار اللبن التلقائي.</p><p>&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">وحتى في حالة تناوله حسب التوجيهات، فيمكن للدواء أن يغير إمكانية رد الفعل إلى حد إمكانية التأثير السلبي على القدرة على القيادة أو استخدام الآلات أو العمل مع موطئ القدم غير الآمن. يتضح ذلك بصفة خاصة عند بدء العلاج، أو إن زادت الجرعة أو تغيّر المستحضر، أو عند إعطاء دواء إضافي مبدئيًا، ومع الكحول. يمكن لهذا الدواء أن يزيد مستويات الكحول في الدم وأن يؤخر التخلص منه، وهو ما يمكن أن يؤدي إلى تعزيز آثار الكحول.</p><p dir="RTL"><strong>إيزوبتين 80 ملجم يحتوي على الصوديوم</strong><strong> </strong></p><p dir="RTL">يحتوي هذا المنتج الدوائي على أقل من 1 ملليمول (23 ملجم) من الصوديوم في كل قرص مغلف بالفيلم، أي أنه يكاد يكون &quot;خاليًا من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">واحرص دومًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. واستشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">يجب تحديد جرعة هيدروكلوريد الفيراباميل، وهي المادة الفعالة في هذا الدواء، على أساس فردي على حسب حدة حالة المريض. وقد أظهرت التجارب السريرية طويلة المدى أن متوسط الجرعة اليومية في جميع دواعي الاستعمال يتراوح ما بين 240 ملجم و360 ملجم يوميًا.</p><p dir="RTL">ويجب ألا تزيد الجرعة اليومية عن 480 ملجم في حالة العلاج على المدى الطويل. في حين يمكن زيادة هذه الجرعة اليومية في حالة العلاج على المدى القصير.</p><p dir="RTL">الجرعة الموصى بها هي:</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يستخدم في البالغين والمراهقين الذين يزيد وزنهم عن 50 كجم:</p><p dir="RTL">الأعراض في الحالات التي تنطوي على الإمداد غير الملائم بالأوكسجين لعضلة القلب (الذبحة الصدرية)</p><p dir="RTL">الجرعة اليومية الموصى بها هي 240 ملجم - 480 ملجم من هيدروكلوريد الفيراباميل مقسمة على 3 إلى 4 جرعات مفردة بما يكافئ:</p><p dir="RTL">1 قرص من هذا الدواء المغلف بطبقة رقيقة 3 إلى 4 مرات يوميًا (ما يكافئ 240 ملجم - 320 ملجم من هيدروكلوريد الفيراباميل يوميًا).</p><p dir="RTL">تتوفر أشكال دوائية ذات تركيزات ملائمة إن كانت هناك حاجة إلى جرعات أعلى (مثل 360 ملجم - 480 ملجم من هيدروكلوريد الفيراباميل يوميًا).</p><p>&nbsp;</p><p dir="RTL"><strong>ارتفاع ضغط الدم</strong></p><p dir="RTL">الجرعة اليومية الموصى بها هي 240 ملجم - 360 ملجم من هيدروكلوريد الفيراباميل مقسمة على 3 جرعات مفردة بما يكافئ:</p><p dir="RTL">قرص واحد من هذا الدواء المغلف بطبقة رقيقة 3 مرات يوميًا (ما يكافئ 240 ملجم من هيدروكلوريد الفيراباميل يوميًا).</p><p dir="RTL">تتوفر أشكال دوائية ذات تركيزات ملائمة إن كانت هناك حاجة إلى جرعات أعلى (مثل 360 ملجم من هيدروكلوريد الفيراباميل يوميًا).</p><p dir="RTL"><strong>عدم انتظام ضربات القلب (تسارع القلب فوق البطيني الانتيابي، الرجفان الأذيني/الرفرفة الأذينية مع سرعة توصيل الأذين البطيني [باستثناء مُتَلاَزِمَة وولف باركنسون هوايت ومتلازمة لاون جانونج ليفين])</strong></p><p dir="RTL">الجرعة اليومية الموصى بها هي 240 ملجم - 480 ملجم من هيدروكلوريد الفيراباميل مقسمة على 3 إلى 4 جرعات مفردة بما يكافئ:</p><p dir="RTL">1 قرص من هذا الدواء المغلف بطبقة رقيقة 3 إلى 4 مرات يوميًا (ما يكافئ 240 ملجم - 320 ملجم من هيدروكلوريد الفيراباميل يوميًا).</p><p dir="RTL">تتوفر أشكال دوائية ذات تركيزات ملائمة إن كانت هناك حاجة إلى جرعات أعلى (مثل 360 ملجم - 480 ملجم من هيدروكلوريد الفيراباميل يوميًا).</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;<strong>الأطفال (لضربات القلب غير المنتظمة فقط):</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال الأكبر سنًا غير البالغين سن الالتحاق بالمدرسة وحتى 6 أعوام:</strong></p><p dir="RTL">الجرعة اليومية الموصى بها هي 80 ملجم - 120 ملجم من هيدروكلوريد الفيراباميل مقسمة على 2 إلى 3</p><p dir="RTL">&nbsp;جرعات مفردة:</p><p dir="RTL">تتوفر أشكال دوائية ذات تركيزات ملائمة (40 ملجم من هيدروكلوريد الفيراباميل) لهذا الغرض.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال في سن المدرسة في أعمار 6-14 عامًا:</strong></p><p dir="RTL">الجرعة اليومية الموصى بها هي 80 ملجم إلى 360 ملجم من هيدروكلوريد الفيراباميل مقسمة على 2 إلى 4</p><p dir="RTL">&nbsp;جرعات فردية، بما يكافئ:</p><p dir="RTL">قرص إلى قرصين من هذا الدواء المغلف بطبقة رقيقة 2 إلى 4 مرات يوميًا (ما يكافئ 160 ملجم - 320 ملجم من هيدروكلوريد الفيراباميل يوميًا).</p><p dir="RTL">يستخدم هذا الدواء بشرط عدم تحقيق الاستجابة المطلوبة بالجرعات الأقل (على سبيل المثال، 80 ملجم من هيدروكلوريد الفيراباميل يوميًا).</p><p dir="RTL">تتوفر أشكال دوائية ذات تركيزات ملائمة إن كانت هناك حاجة إلى جرعات أعلى (مثل 360 ملجم من هيدروكلوريد الفيراباميل يوميًا).</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp; &nbsp;<strong>قصور وظيفة الكلى</strong><br /><br />المعلومات المتاحة حاليًا موصوفة في القسم 2. ينبغي إعطاء هذا الدواء بحذر وتحت المراقبة الصارمة في المرضى بقصور وظيفة الكلى.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;<strong> قصور وظائف الكبد</strong></p><p dir="RTL">يزداد أثر هيدروكلوريد الفيراباميل ومدته في المرضى بقصور وظائف الكبد، ويتوقف ذلك على حدته، لأن الدواء يؤخر الاستقلاب. وفي مثل تلك الحالات، ينبغي ضبط الجرعة بعناية بناءً على ذلك وبواسطة الطبيب، بدءًا بجرعات منخفضة (مثلًا، في المرضى بقصور وظائف لكبد، ينبغي البدء بـ 40 ملجم من هيدروكلوريد الفيراباميل مرتين إلى 3 مرات يوميًا، أي ما يكافئ 80 ملجم - 120 ملجم من هيدروكلوريد الفيراباميل يوميًا) (انظر كذلك القسم 2).</p><p><u>طريقة الاستعمال</u><u> </u></p><p dir="RTL">للاستخدام عن طريق الفم.</p><p dir="RTL">يُرجى تناول هذا الدواء <strong>كاملًا</strong> و<strong>دون مضغه</strong> ومع كمية كافية من السوائل (على سبيل المثال كوب من المياه وليس عصير جريب فروت)، ومن الأفضل أن يكون ذلك أثناء تناول الطعام أو بعد تناوله بوقت قصير.</p><p dir="RTL"><strong>لا تتناول </strong>هذا الدواء <strong>أثناء الاستلقاء</strong>.</p><p dir="RTL">إن وُصف لك هذا الدواء لعلاج الألم وضيق الصدر (الذبحة الصدرية) بعد أزمة قلبية، فلا تتناوله حتى مرور 7 أيام على الأزمة القلبية.</p><p dir="RTL"><u>مدة الاستعمال</u><u> </u></p><p dir="RTL">ولا توجد مدة محددة لتناول الدواء. سيحدد ذلك الطبيب المعالج لك.</p><p dir="RTL">يرجى مناقشة الطبيب أو الصيدلي إذا كنت ترى أن تأثيرات هذا الدواء أقوى من اللازم أو أضعف من اللازم.</p><p><strong>في حالة تناولك جرعة أكبر مما ينبغي من إيزوبتين 80 ملجم</strong></p><p dir="RTL">يمكن أن تظهر العلامات والأعراض السريرية التالية إن تناولت كمية أكبر مما ينبغي من هذا الدواء عن غير قصد أو بقصد:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض خطير في ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات القلب غير المنتظمة (مثل تأخر ضربات القلب أو تسارعها واضطرابات توصيل القلب)، وهو ما قد يؤدي إلى صدمة قلبية وعائية وسكتة قلبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي، ويحتمل أن يتصاعد ذلك إلى غيبوبة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات الجلوكوز في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات البوتاسيوم بالدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض درجة الحموضة في الدم (حماض استقلابي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الأكسجين في أنسجة الجسم (نقص التأكسج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صدمة قلبية وعائية مصحوبة بتجمّع مائي في الرئتين (وذمة رؤية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور وظائف الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات.</p><p>&nbsp;</p><p dir="RTL">تم الإبلاغ أحيانًا عن حدوث حالات وفيات.</p><p dir="RTL">إن ظهر أي من الأعراض التي سبق ذكرها، فاتصل بالطبيب/طبيب الطوارئ فورًا. وسيقوم بالإجراءات اللازمة.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيتَ تناول إيزوبتين</strong><strong> </strong><strong>80 ملجم</strong></p><p dir="RTL">لا تتناول جرعة مزدوجة لتعويض الجرعة المنسية.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول إيزوبتين 80 ملجم</strong></p><p dir="RTL">يُرجى ألا تقطع العلاج بهذا الدواء أو توقفه دون مناقشة ذلك مع طبيبك أولًا.</p><p dir="RTL">لا ينبغي وقف هذا الدواء فجأة بعد العلاج طويل الأمد، ولكن ينبغي إيقافه بالتدريج.</p><p dir="RTL">وإذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن أن يتسبب هذا الدواء مثل جميع الأدوية في حدوث آثار جانبية، على الرغم من عدم تعرض الجميع لها.</p><p dir="RTL">تُستخدم الفئات التالية لتحديد معدل تكرار الآثار الجانبية:</p><p dir="RTL">آثار شائعة جدًا:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تصيب أكثر من 1 بين 10 مرضى</p><p dir="RTL">آثار شائعة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تصيب ما يصل إلى مريض واحد من بين كل 10 مرضى</p><p dir="RTL">آثار غير شائعة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تصيب ما يصل إلى مريض واحد من بين 100 مريض</p><p dir="RTL">نادرة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تصيب ما يصل إلى مريض واحد من بين 1000 مريض</p><p dir="RTL">آثار نادرة جدًا:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تصيب ما يصل إلى مريض واحد من بين 10,000 مريض</p><p dir="RTL">آثار غير معروفة:&nbsp; يتعذر تقدير معدل التكرار بناء على البيانات المتاحة</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية غير شائعة</strong> (قد تصيب ما يصل إلى 1 بين 10 مرضى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة أو الدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعتلال الأعصاب (اضطرابات الجهاز العصبي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تباطؤ ضربات القلب (تباطؤ القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بدء الإصابة بفشل القلب أو احتدام إصابة سابقة بفشل القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبوط مفرط في ضغط الدم و/أو حدوث اضطرابات نتيجة لهبوط ضغط الدم عند تغيير وضعية الجسم من الاستلقاء أرضًا أو الجلوس إلى الوقوف (الخلل الوظيفي الانتصابي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبيغ (احمرار الوجه مع شعور بحرارة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم (هبوط ضغط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار وتورّم مؤلم في الأطراف (احمرار الأطراف المؤلم )</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وذمة بالكاحل (وذمة محيطية)</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة </strong>(يمكن أن يتأثر به ما يصل إلى 1 بين 100 مريض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تحمل الجلوكوز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخفقان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات القلب السريعة (تسرع القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ربما يحدث التهاب بالكبد الذي يسببه الحساسية (التهاب الكبد) مع زيادة في إنزيمات محددة بالكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإجهاد</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة </strong>(يمكن أن يتأثر به ما يصل إلى 1 بين 1000 مريض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحاسيس غير طبيعية مثل وخز واخْدِرار أو برودة في الأطراف (مَذَل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس/دوار/توهان (نعاس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طنين في الأذنين (طنين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التعرّق (فَرْطُ التَّعَرُّق)</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة للغاية </strong>(يمكن أن يتأثر به ما يصل إلى 1 بين 10000 شخص يتلقى العلاج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل بالجلد مشابهة لحروق الشمس (التهاب الجلد الضوئي المنشأ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم بعض الاضطرابات العضلية (<em>الوهن العضلي الوبيل</em>، متلازمة لامبرت إيتون، أو الضمور العضلي الدوشيني)</p><p>&nbsp;</p><p dir="RTL"><strong>حدثت الآثار الجانبية التالية بمعدل تكرار لا يمكن تقديره على أساس البيانات المتاحة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية المفرطة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات لا إرادية غير طبيعية (أعراض خارج السبيل الهرمي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شلل (خزل رباعي)<br />(كان يوجد تقرير منفرد لما بعد التسويق بخصوص الشلل، وتحديدًا عن ضعف الذراعين والساقين (الخزل الرباعي،) مرتبط بالاستخدام المتزامن لهيدروكلوريد الفيراباميل (المادة الفعالة في هذا الدواء) والكولشيسين (المادة الفعالة لعلاج النقرس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط تركيزات البوتاسيوم في الدم (فرط بوتاسيوم الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة (الدوار)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات خطيرة في توصيل القلب [إحصار أذيني بطيني (من الدرجة <sup>الأولى </sup>&nbsp;والثانية<sup>و</sup> الثالثة)]</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل القلب (قصور القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التوقف جيبي المنشأ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء القلب جيبي المنشأ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقف القلب (توقف الانقباض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج العضلات الملساء بالقصبات الهوائية (تشنج القصبات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط نمو أنسجة اللثة (فرط تنسج اللثة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأمعاء (العِلَّوص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الأنسجة، خاصة في الوجه (وذمة وعائية عصبية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي حاد بالجلد مع تأثير بالغ على الحالة العامة (متلازمة ستيفنز جونسون)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمامي عديدة الأشكال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر (الثعلبة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُكَاك (حِكَّة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع على الجلد أو غشاء مخاطي بسبب النزيف (فرفرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مع وجود بقع وتَحاديب على سطح الجلد (طفح بقعي حطاطي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى قراصية (شَرَى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل (الألم المفصلي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات (الألم العضلي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكلوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العجز الجنسي (ضعف الانتصاب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفريغ الحليب (ثرّ اللبن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخّم أنسجة الثدي لدى الذكور (التثدي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة قيم البرولاكتين في الدم</p><p><strong>ملاحظة</strong></p><p dir="RTL">لا يمكن استبعاد الأثر السلبي على وظيفة منظم نبض القلب أثناء العلاج بهيدروكلوريد الفيراباميل في المرضى الذين جرى تركيب منظم نبض قلب لهم.</p><p>الإجراءات المضادة</p><p dir="RTL">إن لاحظت أيًا من الآثار الجانبية سابقة الذكر، فأبلغ طبيبك بحيث يمكن أن يحدد حدتها ويتخذ أي إجراءات قد تكون ضرورية.</p><p>&nbsp;</p><p><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أُصبتِ بأي آثار جانبية، فتحدثِي مع الطبيب أو الصيدلي. يشمل ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات بشأن سلامة هذا الدواء.</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ والسلامة الدوائية (</strong><strong>NPC)</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-11-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال: 19999</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ هذا الدواء بعيدًا عن متناول ومرأى الأطفال.</p><p dir="RTL">يحفظ في درجة حرارة لا تزيد عن 30 درجة مئوية.</p><p dir="RTL"><strong>فترة الصلاحية:</strong><strong> </strong>36 شهرًا.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية وشريط البليستر بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف الصحي أو المخلفات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من أي أدوية لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المادة الفعّالة</strong> هي هيدروكلوريد الفيراباميل.</p><p dir="RTL">يحتوي كل قرص مغلف بالفيلم على 80 ملجم من هيدروكلوريد الفيراباميل.</p><p dir="RTL"><strong>المكونات</strong> <strong>الأخرى </strong>هي:<br />ثنائي هيدرات فوسفات هيدروجين الكالسيوم، كروس كارميلوز الصوديوم؛ وثاني أكسيد السليكون عالي الانتشار؛ هيبروميللوز؛ ماكروجول 6000؛ ماغنسيوم ستيريت (دستور الأدوية الأوروبي)؛ سيليلوز بلوري مكروي؛ سلفات دوديسيل الصوديوم؛ تلك؛ ثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص مغلفة بيضاء ومقوسة، مع كتابة &quot;Isopin 80&quot; على أحد الجوانب و&quot;Knoll&quot; على الجانب الآخر. عبوة بها 20 أو 50 أو 100 قرص مغلّف</p><p>&nbsp;</p><p dir="RTL">قد لا تتوفر جميع الأشكال وأحجام العبوات في الأسواق.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق:</strong></p><p dir="RTL">Abbott Laboratories GmbH,</p><p dir="RTL">&nbsp;هانوفر، ألمانيا</p><p>&nbsp;</p><p dir="RTL"><strong>جهة التصنيع:</strong></p><p dir="RTL">Famar A.V.E, Anthoussa Avenue 7,</p><p>&nbsp;&nbsp; Anthoussa, Attiki, 15349 اليونان</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            07/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Isoptin 80 mg
Film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active substance: verapamil hydrochloride
Each film-coated tablet contains 80 mg verapamil hydrochloride.

Excipients with known effect:
Isoptin 80 mg contains less than 1 mmol (23 mg) sodium per film-coated tablet.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Symptomatic coronary heart disease:</li></ul><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic stable angina pectoris (angina of effort)</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unstable angina pectoris (crescendo angina, angina at rest)</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vasospastic angina pectoris (Prinzmetal&rsquo;s angina, variant angina)</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angina pectoris post myocardial infarction in patients without heart failure, when beta blockers are not indicated.</p><ul><li>&nbsp; &nbsp; &nbsp; &nbsp; Arrhythmias in the case of:</li></ul><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; paroxysmal supraventricular tachycardia</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; atrial fibrillation/atrial flutter with rapid AV conduction [except in WPW (Wolff-Parkinson-White) syndrome or Lown-Ganong-Levine syndrome, see under section 4.3]</p><ul><li>&nbsp; &nbsp; &nbsp; &nbsp; Hypertension</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The dose of verapamil hydrochloride, the active substance contained in Isoptin, should be adjusted on an individual basis, depending on the severity of the disease. Long-standing clinical experience shows that the average daily dose in almost all indications is between 240 mg and 360 mg.</p><p>A daily dose of 480 mg should not be exceeded in long-term therapy. It may be increased for a short period.</p><p>Unless otherwise prescribed, the following dosing guidelines apply:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp;&nbsp; Adults and adolescents weighing over 50 kg:</strong></p><p><strong>Coronary heart disease</strong></p><p>The recommended dose is 240 mg &ndash; 480&nbsp;mg verapamil hydrochloride per day in 3 to 4 divided doses, equivalent to:</p><p>1 film-coated tablet of this medicinal product 3 &ndash; 4 times daily (equivalent to 240 mg &ndash; 320 mg verapamil hydrochloride per day).</p><p>Pharmaceutical forms with appropriate strengths are available if higher doses (e.g. 360 mg &ndash; 480 mg verapamil hydrochloride) are required.</p><p><strong>Hypertension</strong></p><p>The recommended dose is 240 mg &ndash; 360 mg verapamil hydrochloride per day in 3 divided doses, equivalent to:</p><p>1 film-coated tablet of this medicinal product 3 times daily (equivalent to 240 mg verapamil hydrochloride per day).</p><p>Pharmaceutical forms with appropriate strengths are available if higher doses (e.g. 360 mg verapamil hydrochloride) are required.</p><p><strong>Paroxysmal, supraventricular tachycardia, atrial fibrillation/atrial flutter</strong></p><p>The recommended dose is 240 mg &ndash; 480&nbsp;mg verapamil hydrochloride daily in 3 to 4 divided doses, equivalent to:</p><p>1 film-coated tablet of this medicinal product 3 to 4 times daily (equivalent to 240 mg&nbsp;&ndash; 320 mg verapamil hydrochloride per day).</p><p>Pharmaceutical forms with appropriate strengths are available if higher doses (e.g. 360 mg &ndash; 480 mg verapamil hydrochloride) are required.</p><p>&middot;&nbsp;&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paediatric group (for arrhythmias only):</strong></p><p><strong>Older pre-school children up to 6 years:</strong></p><p>The recommended dose is 80 mg &ndash; 120 mg verapamil hydrochloride daily in 2 to 3 divided&nbsp;</p><p>doses, equivalent to:</p><p>&nbsp;</p><p>Pharmaceutical forms with appropriate strengths (40 mg verapamil hydrochloride) are available for this purpose.</p><p>&nbsp;</p><p><strong>School children 6 &ndash; 14 years:</strong></p><p>The recommended dose is 80 mg &ndash; 360 mg verapamil hydrochloride daily in 2 to 4 divided&nbsp;</p><p>doses, equivalent to:</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 film-coated tablet of this medicinal product 2 to 4 times a day (equivalent to 160 mg &ndash;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 320 mg verapamil hydrochloride per day).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p>This medicinal product is used if no adequate effect has been achieved with lower doses (e.g. 80 mg verapamil hydrochloride per day).</p><p>Pharmaceutical forms with appropriate strengths are available if higher doses (e.g. 360 mg verapamil hydrochloride) are required.</p><p><strong><u>Impaired renal function</u></strong></p><p>The information currently available is described in section 4.4.</p><p>Verapamil hydrochloride should be used with caution and under close monitoring in patients with renal impairment.</p><p><strong><u>Impaired hepatic function</u></strong></p><p>Depending on the severity of the condition, the effect of verapamil hydrochloride is potentiated and prolonged in patients presenting impaired hepatic function because of slower drug decomposition. In such cases, the dosage should therefore be adjusted with particular caution, starting with lower doses (e.g. in patients with hepatic impairment, initially 40&nbsp;mg verapamil hydrochloride, 2 to 3 times a day, corresponding to 80&nbsp;mg &ndash; 120&nbsp;mg verapamil hydrochloride per day) (see also section 4.4).</p><p><u>Method and duration of administration</u></p><p>The medicinal product should be taken whole and unchewed, with sufficient fluid intake (e.g. a glass of water, no grapefruit juice) preferably with or shortly after food.</p><p>Verapamil should not be taken in the supine position.</p><p>In patients presenting Angina pectoris post myocardial infarction, verapamil should not be taken until 7 days after acute infarction.</p><p>The duration of administration is not limited.</p><p>Following long-term therapy, verapamil should not, in principle, be discontinued abruptly but gradually decreased.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Isoptin 80 mg should not be used in the case of:
•	hypersensitivity to the active substance or to any of the excipients listed in section 6.1
•	cardiovascular shock
•	pronounced cardiac conduction disorders (e.g. IInd and IIIrd degree SA or AV block; except for patients fitted with a pacemaker)
•	sick sinus syndrome (except for patients fitted with a pacemaker)
•	heart failure with a reduced ejection fraction of less than 35% and/or wedge pressure exceeding 20 mmHg (unless secondary to supraventricular tachycardia responding to verapamil)
•	atrial fibrillation/flutter and the concomitant presence of accessory pathways (e.g. WPW or Lown-Ganong-Levine syndrome). In these patients, verapamil therapy poses an increased risk of ventricular tachycardia, including ventricular fibrillation
•	concomitant administration of ivabradine (see also section 4.5)
Beta blockers should not be administered intravenously in conjunction with verapamil (except in intensive care medicine; see also section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Acute myocardial infarction</em></strong></p><p>Verapamil should only be used with caution in the case of acute myocardial infarction with complications (bradycardia, hypotension, left-sided ventricular heart failure).</p><p><strong><em>Conduction disorder</em>/<em>Ist degree AV block/bradycardia/asystole</em></strong></p><p>Verapamil affects AV and sinus nodes and delays AV conduction. It should be used with caution since IInd or IIIrd degree AV block (contraindication) or unifascicular, bifascicular or trifascicular bundle branch block warrants discontinuation of treatment and the initiation of appropriate therapy, if required.</p><p>Verapamil affects AV and sinus nodes and, in rare cases, may trigger IInd or IIIrd degree AV block, bradycardia or, in extreme cases, asystole. This is more likely to occur in patients with sick sinus syndrome, which is more common in older patients.</p><p>In patients not suffering from sick sinus syndrome, asystole is normally of short duration (a few seconds or less), with a spontaneous return to AV-node or normal sinus rhythm. If this does not occur immediately, appropriate treatment should be initiated without delay (see also section 4.8).</p><p><strong><em>Antiarrhythmics, beta blockers and inhalation anaesthetics</em></strong></p><p>Antiarrhythmics (e.g. flecainide, disopyramide), beta receptor blockers (e.g. metoprolol, propranolol) and inhalation anaesthetics may mutually potentiate cardiovascular effects (severe AV block, severe drop in heart rate, onset of heart failure, marked hypotension) if administered concomitantly with verapamil (see also section 4.5).</p><p>&nbsp;</p><p>Asymptomatic bradycardia (36&nbsp;beats per minute) with a migrating atrial pacemaker was observed in one patient using eye drops containing timolol (a beta blocker) and taking verapamil concomitantly.</p><p><strong><em>Digoxin</em></strong></p><p>The digoxin dose should be reduced if taken concomitantly with verapamil (see also section 4.5).</p><p><strong><em>Heart failure</em></strong></p><p>Heart failure patients with an ejection fraction of over 35% should be compensated before treatment begins. Adequate therapy should also be administered during treatment.</p><p><strong><em>HMG-CoA reductase inhibitors (&ldquo;statins&rdquo;)</em></strong></p><p>See section 4.5.</p><p><strong><em>Disorders with impaired neuromuscular transmission</em></strong></p><p>Caution should be exercised when prescribing verapamil for patients previously diagnosed with impaired neuromuscular transmission (<em>Myasthenia gravis</em>, Lambert-Eaton syndrome, progressive Duchenne muscular dystrophy).</p><p><strong><em>Hypotension</em></strong></p><p>Particularly strict monitoring is required in the case of hypotension (less than 90&nbsp;mmHg systolic).</p><p><strong><u>Further information</u></strong></p><p><strong><em>Special patient groups</em></strong></p><p><strong><em>Impaired renal function</em></strong></p><p>Although comparative studies have reliably shown that impaired renal function in patients presenting end-stage renal failure has no effect on the pharmacokinetic profile of verapamil, individual case reports suggest that caution should be exercised and strict monitoring implemented (ECG, blood pressure) when administering verapamil to patients with renal impairment.</p><p>Verapamil cannot be removed through haemodialysis.</p><p><strong><em>Impaired hepatic function</em></strong></p><p>Use with caution in patients with severely compromised hepatic function (see also information on impaired hepatic function in section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In-vitro</em> studies have shown that verapamil is metabolised by cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C8, CYP2C9 and CYP2C18.</p><p>Clinically significant interactions have been reported with CYP3A4 inhibitors responsible for increased verapamil hydrochloride plasma levels; contrastingly, inducers of CYP3A4 lower verapamil hydrochloride plasma levels. Patients should therefore be monitored for interactions.</p><p>Verapamil inhibits CYP3A4 and P-glycoprotein (P-gp). Concomitant administration of verapamil and another medicinal product, mainly metabolised via CYP3A4 or representing a P-gp substrate, can increase the active substance concentration of the concomitant medicinal product, thus potentiating or prolonging the therapeutic effect and increasing the adverse events associated with the concomitant medication.</p><p>Potential pharmacokinetic interactions are highlighted in the following table:</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="3" style="vertical-align:top"><p><strong>Potential interactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Concomitant medication</strong></p></td><td style="vertical-align:top"><p><strong>Potential effect on verapamil or the concomitant medication</strong></p></td><td style="vertical-align:top"><p><strong>Comment</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Alpha blockers</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Prazosin</p></td><td style="vertical-align:top"><p>c<sub>max</sub> of prazosin &shy; (~&nbsp;40%), no effect on half-life</p></td><td rowspan="2" style="vertical-align:top"><p>Additive antihypertensive effect</p></td></tr><tr><td style="vertical-align:top"><p>Terazosin</p></td><td style="vertical-align:top"><p>&shy; in the AUC (~&nbsp;24%) and (25%) of terazosin</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Antiarrhythmics</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Flecainide</p></td><td style="vertical-align:top"><p>Minimal effect on plasma clearance of flecainide (&lt;&nbsp;~&nbsp;10%); no effect on verapamil plasma clearance</p></td><td style="vertical-align:top"><p>Further information (see under section 4.4 - Antiarrhythmics, beta receptor blockers and inhalation anaesthetics)</p></td></tr><tr><td style="vertical-align:top"><p>Quinidine</p></td><td style="vertical-align:top"><p>Clearance of oral quinidine</p><p>&macr; (~&nbsp;35%)</p></td><td style="vertical-align:top"><p>Hypotension.</p><p>&nbsp;</p><p>Pulmonary oedema may occur in patients with hypertrophic obstructive cardiomyopathy.</p></td></tr><tr><td style="vertical-align:top"><p>Amiodarone</p></td><td style="vertical-align:top"><p>Increase in amiodarone plasma levels</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Antiasthmatics</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Theophylline</p></td><td style="vertical-align:top"><p>Oral and systemic clearance</p><p>&macr; by ~&nbsp;20%</p></td><td style="vertical-align:top"><p>The reduction in clearance was less pronounced in smokers (~&nbsp;11%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Anticonvulsives/Antiepileptics</em></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Carbamazepine</p></td><td style="vertical-align:top"><p>AUC of carbamazepine &shy; (~&nbsp;46%) in patients with refractory partial epilepsy</p></td><td rowspan="2" style="vertical-align:top"><p>Increased carbamazepine levels.</p><p>&nbsp;</p><p>This may trigger adverse events such as diplopia, headaches, ataxia or dizziness/vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Reduction in verapamil hydrochloride plasma levels</p></td></tr><tr><td style="vertical-align:top"><p>Phenytoin</p></td><td style="vertical-align:top"><p>Verapamil plasma concentrations &macr;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Antidepressants</em></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Imipramine</p></td><td style="vertical-align:top"><p>AUC of imipramine &shy; (~&nbsp;15%)</p></td><td rowspan="2" style="vertical-align:top"><p>No effect on the levels of the active metabolite desipramine.</p></td></tr><tr><td style="vertical-align:top"><p>Increased verapamil hydrochloride plasma levels</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Antidiabetics</em></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Glibenclamide</p></td><td style="vertical-align:top"><p>c<sub>max</sub> (~&nbsp;28%) and AUC of glibenclamide &shy; (~&nbsp;26%)</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Increased verapamil hydrochloride plasma levels</p></td></tr><tr><td style="vertical-align:top"><p>Metformin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Co-administration of verapamil with metformin may reduce the efficacy of metformin.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Gout treatments</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Colchicine</p></td><td style="vertical-align:top"><p>&shy; of AUC (~&nbsp;2.0-fold) and c<sub>max</sub> (~&nbsp;1.3-fold) of colchicine</p></td><td style="vertical-align:top"><p>Reduction in the dose of colchicine (concomitant use of colchicine with verapamil hydrochloride is not recommended).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Anti-infectives</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Clarithromycin</p></td><td style="vertical-align:top"><p>Potential &shy; in verapamil levels</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin</p></td><td style="vertical-align:top"><p>Potential &shy; in verapamil levels</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Rifampicin</p></td><td style="vertical-align:top"><p>With oral administration of verapamil &macr; in AUC (~&nbsp;97%), c<sub>max</sub> (~&nbsp;94%) and oral bioavailability (~&nbsp;92%) of verapamil</p></td><td rowspan="2" style="vertical-align:top"><p>Potential reduction in anti-hypertensive effect.</p></td></tr><tr><td style="vertical-align:top"><p>No change in the PC with intravenous administration of verapamil</p></td></tr><tr><td style="vertical-align:top"><p>Telithromycin</p></td><td style="vertical-align:top"><p>Possible &shy; in verapamil levels</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Antineoplastics</em></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Doxorubicin</p></td><td style="vertical-align:top"><p>With oral administration of verapamil &shy; in AUC (104%) and c<sub>max</sub> (61%) of doxorubicin</p></td><td style="vertical-align:top"><p>In patients with small-cell lung cancer.</p></td></tr><tr><td style="vertical-align:top"><p>No significant changes in the PC of doxorubicin with intravenous use of verapamil</p></td><td style="vertical-align:top"><p>In patients with advanced tumours.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Azole fungistatics</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Clotrimazole</p></td><td style="vertical-align:top"><p>Increased verapamil hydrochloride plasma levels</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ketoconazole</p></td><td style="vertical-align:top"><p>Increased verapamil hydrochloride plasma levels</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole</p></td><td style="vertical-align:top"><p>Increased verapamil hydrochloride plasma levels</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Barbiturates</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Phenobarbital</p></td><td style="vertical-align:top"><p>Clearance of oral verapamil &shy; (~&nbsp;5-fold)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Benzodiazepines and other anxiolytics</em></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Buspirone</p></td><td style="vertical-align:top"><p>AUC and c<sub>max</sub> of buspirone &shy; (~&nbsp;3.4-fold)</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Increased verapamil hydrochloride plasma levels</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Midazolam</p></td><td style="vertical-align:top"><p>AUC (~&nbsp;3-fold) and c<sub>max</sub> (~&nbsp;2-fold) of Midazolam &shy;</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Increased verapamil hydrochloride plasma levels</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Beta blockers</em></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metoprolol</p></td><td style="vertical-align:top"><p>In patients with angina pectoris &shy; in the AUC (~&nbsp;32.5%) and c<sub>max</sub> (~&nbsp;41%) of metoprolol</p></td><td rowspan="4" style="vertical-align:top"><p>See Section 4.4.</p></td></tr><tr><td style="vertical-align:top"><p>Increased verapamil hydrochloride plasma levels</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Propranolol</p></td><td style="vertical-align:top"><p>In patients with angina pectoris &shy; in AUC (~&nbsp;65%) and c<sub>max</sub> (~&nbsp;94%) of propranolol</p></td></tr><tr><td style="vertical-align:top"><p>Increased verapamil hydrochloride plasma levels</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Cardiac glycosides</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Digitoxin</p></td><td style="vertical-align:top"><p>&macr; in total clearance of digitoxin (~&nbsp;27%) and in extrarenal clearance (~&nbsp;29%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Digoxin</p></td><td style="vertical-align:top"><p>In healthy subjects: c<sub>max</sub> of digoxin &shy; (~&nbsp;44%), c<sub>12&nbsp;h</sub> of digoxin &shy; (~&nbsp;53%), c<sub>SS</sub> of digoxin &shy; (~&nbsp;44%) and AUC of digoxin &shy; (~&nbsp;50%)</p></td><td style="vertical-align:top"><p>Reduction in digoxin dose (see also section 4.4.)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>H2-receptor antagonists</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Cimetidine</p></td><td style="vertical-align:top"><p>AUC of R- (~&nbsp;25%) and S-verapamil (~&nbsp;40%) with corresponding &macr; in the clearance of R- and S-verapamil</p></td><td style="vertical-align:top"><p>Cimetidine reduces verapamil clearance after intravenous administration of verapamil.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Immunological agents/Immunosuppressants</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Cyclosporine</p></td><td style="vertical-align:top"><p>AUC, c<sub>SS</sub>, c<sub>max</sub> of cyclosporine &shy; (~&nbsp;45%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Everolimus</p></td><td style="vertical-align:top"><p>Everolimus-AUC &shy; (~&nbsp;3.5-fold), c<sub>max</sub> &shy; (~&nbsp;2.3-fold),</p><p>verapamil: c<sub>trough</sub> &shy; (~&nbsp;2.3-fold)</p></td><td style="vertical-align:top"><p>Potential determination of concentration and dose adjustment of everolimus required.</p></td></tr><tr><td style="vertical-align:top"><p>Sirolimus</p></td><td style="vertical-align:top"><p>Sirolimus-AUC &shy; (~&nbsp;2.2-fold);</p><p>S-verapamil-AUC &shy; (~&nbsp;1.5-fold)</p></td><td style="vertical-align:top"><p>Potential determination of concentration and dose adjustment of sirolimus necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Tacrolimus</p></td><td style="vertical-align:top"><p>Tacrolimus levels possibly &shy;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Lipid-lowering/HMG-CoA reductase inhibitors</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Atorvastatin</p></td><td style="vertical-align:top"><p>Possible &shy; in atorvastatin levels</p><p>AUC of verapamil &shy; (~&nbsp;43%)</p></td><td rowspan="3" style="vertical-align:top"><p>Further information see below.</p></td></tr><tr><td style="vertical-align:top"><p>Lovastatin</p></td><td style="vertical-align:top"><p>Possible &shy; in lovastatin levels</p><p>AUC (~&nbsp;63%) and c<sub>max</sub> (~&nbsp;32%) of verapamil &shy;</p></td></tr><tr><td style="vertical-align:top"><p>Simvastatin</p></td><td style="vertical-align:top"><p>AUC (~&nbsp;2.6-fold) and c<sub>max</sub> (~&nbsp;4.6-fold) of simvastatin &shy;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Serotonin receptor agonists</em></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Almotriptan</p></td><td style="vertical-align:top"><p>AUC (~&nbsp;20%) and c<sub>max</sub> (~&nbsp;24%) of almotriptan &shy;</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Increased verapamil hydrochloride plasma levels</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Uricosuric agents</em></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Sulfinpyrazone</p></td><td style="vertical-align:top"><p>Oral clearance of verapamil &shy; (~&nbsp;3-fold), bioavailability &macr; (~&nbsp;60%)</p></td><td rowspan="2" style="vertical-align:top"><p>Potential reduction in antihypertensive effect</p></td></tr><tr><td style="vertical-align:top"><p>No change in the PC with intravenous use of verapamil</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Other cardiac treatments</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Ivabradine</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Concomitant use with ivabradine is contraindicated due to the additional heart rate-reducing effect of verapamil on ivabradine.</p></td><td style="vertical-align:top"><p>See section 4.3</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Other</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Grapefruit juice</p></td><td style="vertical-align:top"><p>&shy; in AUC of R- (~&nbsp;49%) or S-verapamil (~&nbsp;37%)</p><p>&shy; in the c<sub>max</sub> of R- (~&nbsp;75%) or S-verapamil (~&nbsp;51%)</p></td><td style="vertical-align:top"><p>Elimination half-life and renal clearance not affected.</p><p>Food and drink containing grapefruit should be avoided whilst using verapamil.</p></td></tr><tr><td style="vertical-align:top"><p>St. John&rsquo;s wort</p></td><td style="vertical-align:top"><p>&macr; in the AUC of R- (~&nbsp;78%) or S-verapamil (~&nbsp;80%) with corresponding reduction in c<sub>max</sub></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong><u>Other interactions and additional information</u></strong></p><p><strong><em>HIV antiviral drugs</em></strong></p><p>Verapamil plasma concentrations may increase due to the inhibiting potential of some HIV antiviral drugs, such as ritonavir. They should therefore be used with caution and the dose of verapamil should be reduced if necessary.</p><p>Similarly, verapamil may increase the plasma levels of these medicinal products by influencing degradation.</p><p><strong><em>Lithium</em></strong></p><p>Increased sensitivity to the effects of lithium (neurotoxicity) have been reported following concomitant administration with lithium; lithium levels were unchanged or increased during treatment.</p><p>The administration of verapamil has, however, also led to a reduction in serum lithium levels in patients receiving long-term oral lithium therapy. Patients receiving both active substances should therefore be closely monitored.</p><p><strong><em>Muscle relaxants</em></strong></p><p>Both clinical and experimental animal data show that verapamil may potentiate the effects of muscle relaxants (both curare and depolarising). It may therefore be necessary to reduce the verapamil dose and/or the dose of the muscle relaxant, if both are administered concomitantly.</p><p><strong><em>Acetylsalicylic acid</em></strong></p><p><em>Increased propensity to bleed</em><em>.</em></p><p>&nbsp;&nbsp;<strong>Dabigatran</strong></p><p>Elevated dabigatran Cmax and AUC levels were recorded following concomitant administration of oral verapamil and dabigatran etexilate (150 mg), a substrate of P-gp. The extent of these changes depends on the time of administration and the verapamil formulation used.</p><p>Dabigatran C<sub>max </sub>&nbsp;levels and the AUC increased by approximately 180% and 150%, respectively, following the administration of a rapid-release formulation of verapamil 120 mg one hour before a single dose of dabigatran etexilate. No significant interactions were observed when verapamil was administered 2 hours after dabigatran etexilate (increases of approximately 10% and 20% in C<sub>max</sub> and AUC, respectively).</p><p>Close clinical monitoring is recommended if verapamil is combined with dabigatran etexilate, especially in the event of bleeding and particularly in patients with mild to moderate renal impairment.</p><p><strong><em>Other direct oral anticoagulants (DOACs)</em></strong></p><p>Both CYP3A4 and P-gp inhibitors such as verapamil can increase DOAC plasma concentrations to a clinically relevant extent. Some data suggest a potential increase in the risk of bleeding, particularly in patients presenting risk factors. The DOAC dose should be reduced during concomitant administration of verapamil, if required (see dosing instructions in the DOAC package leaflet/SmPC).</p><p><strong><em>Ethanol (Alcohol)</em></strong></p><p>Delayed ethanol degradation and elevated ethanol plasma levels, thus potentiating the effect of alcohol.</p><p><strong><em>HMG-CoA reductase inhibitors (statins)</em></strong></p><p>In patients receiving verapamil, HMG-CoA reductase inhibitor treatment (e.g. simvastatin, atorvastatin or lovastatin) should be started at the lowest possible dose and up-titrated. If verapamil is added to existing HMG-CoA reductase inhibitor therapy (e.g. simvastatin, atorvastatin or lovastatin), a statin dose reduction should be considered, with back-titration against the serum cholesterol concentration.</p><p>&nbsp;</p><p>The risk of myopathy/rhabdomyolysis is increased following concomitant administration of higher doses of verapamil and simvastatin. The simvastatin dose should be adjusted accordingly (see the manufacturer&rsquo;s production information; see also section 4.4).</p><p>Fluvastatin, pravastatin and rosuvastatin are not metabolised via cytochrome P450 isoenzyme 3A4. An interaction with verapamil is less likely.</p><p><strong><em>Antihypertensives, diuretics, vasodilators:</em></strong></p><p>Potentiation of the antihypertensive effect with the risk of excessive hypotension.</p><p><strong><em>Antiarrhythmics (e.g. flecainide, disopyramide), beta blockers (e.g. metoprolol, propranolol), inhalation anaesthetics:</em></strong></p><p>Mutual potentiation of cardiovascular effects (severe AV block, severe drop in heart rate, onset of heart failure, exacerbated hypotension).</p><p>Intravenous beta receptor blockers should not be administered concomitantly to patients receiving intravenous verapamil hydrochloride (except in intensive care; see also section 4.3). Concomitant administration of intravenous verapamil hydrochloride and anti-adrenergic agents may lead to excessive hypotension. Simultaneous administration of intravenous beta blockers or disopyramide with intravenous verapamil increased the risk of adverse events, particularly in patients with a history of cardiovascular disease, e.g. severe cardiomyopathy, congestive heart failure or recent myocardial infarction, since both substance classes suppress myocardial contractility and AV conduction (see also section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Verapamil can cross the placenta. The plasma concentration in umbilical vein blood amounts to 20 - 92% of the plasma concentration in the maternal blood. There is inadequate experience of the use of verapamil hydrochloride during pregnancy. However, data on a limited number of orally treated pregnant women do not associate teratogenic effects with verapamil hydrochloride. Animal studies have highlighted reproduction toxicity (see section 5.3.).</p><p>Therefore, verapamil hydrochloride should not be taken during the first and second trimesters of pregnancy. It should only be administered in the third trimester of pregnancy if strictly indicated, taking into account the risk for mother and child.</p><p><u>Breast-feeding</u></p><p>Verapamil diffuses into breast milk (milk concentration approx. 23% of maternal plasma concentration). Limited human data following oral administration have shown that the nursing infant absorbs only a small quantity of active substance (0.1 to 1% of the maternal dose). Treatment may therefore be compatible with breast-feeding.</p><p>A risk to the new-born/nursing infant cannot be ruled out. Hence, given the risk of serious adverse events in the nursing infant, verapamil should only be administered during breast-feeding if deemed absolutely essential for the mother&rsquo;s well-being.</p><p>There is evidence to suggest that verapamil hydrochloride may cause hyperprolactinaemia and galactorrhoea in individual cases.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients must be monitored regularly during verapamil therapy. Given the variation in individual reactions, the ability to react may be changed to such an extent that the ability to drive, use machines or work without secure footing is adversely affected. This applies in particular at the start of treatment, if the dosage is increased or the preparation changed, and in combination with alcohol. Blood alcohol levels may be increased and the elimination of alcohol slowed down, thus potentially enhancing the effects of alcohol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following undesirable effects have been reported in clinical trials, post-marketing studies or phase IV clinical trials; they are ranked according to system organ class.</p><p>The frequency data are defined as follows:</p><p>Very common: may affect more than 1 in 10 patients treated</p><p>Common: may affect up to 1 in 10 patients treated</p><p>Uncommon: may affect up to 1 in 100 patients treated</p><p>Rare: may affect up to 1 in 1,000 patients treated</p><p>Very rare: may affect up to 1 in 10,000 patients treated</p><p>Unknown: frequency cannot be estimated from the available data</p><p>The most commonly reported undesirable effects were headaches, dizziness or giddiness, gastrointestinal disorders (nausea, constipation, abdominal discomfort), as well as bradycardia, tachycardia, palpitations, hypotension, flushes, peripheral oedema and fatigue.</p><p>Undesirable effects reported from clinical studies with verapamil and post-marketing observations</p><table border="1" cellspacing="0" cellpadding="0" style="width:660px"><thead><tr><td style="vertical-align:top"><p><strong>MedDRA</strong></p><p><strong>system organ class</strong></p></td><td style="vertical-align:top"><p><strong>common</strong></p></td><td style="vertical-align:top"><p><strong>uncommon</strong></p></td><td style="vertical-align:top"><p><strong>rare</strong></p></td><td style="vertical-align:top"><p><strong>very rare</strong></p></td><td style="vertical-align:top"><p><strong>unknown</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Immune system </strong>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system </strong>disorders</p></td><td style="vertical-align:top"><p>Dizziness or giddiness, headaches, neuropathy</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Paraesthesia,</p><p>Tremor</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Extrapyramidal symptoms, paralysis (tetraparesis)<sup>1</sup>, cramps</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism </strong>and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Reduced glucose tolerance</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperkaliaemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric </strong>disorders</p></td><td style="vertical-align:top"><p>Anxiety</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Drowsiness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear </strong>and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac </strong>disorders</p></td><td style="vertical-align:top"><p>Bradycardia,</p><p>onset of heart failure or exacerbation of pre-existing heart failure, excessive blood pressure reduction and/or orthostatic regulation disorders</p></td><td style="vertical-align:top"><p>Palpitations, tachycardia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>AV block (Ist, IInd or IIIrd degree), heart failure, sinus arrest, sinus bradycardia, asystole</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Flushes, hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, </strong>thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bronchospasm,</p><p>dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal </strong>disorders</p></td><td style="vertical-align:top"><p>Constipation, nausea</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abdominal discomfort, gingival hyper&shy;plasia, ileus</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Probably allergy-induced hepatitis with reversible increase in liver-specific enzymes.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin </strong>and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Erythromelalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperhidrosis</p></td><td style="vertical-align:top"><p>Photodermatitis</p></td><td style="vertical-align:top"><p>Angioedema, Stevens-Johnson syndrome, erythema multiforme, alopecia, itching, pruritus, purpura, maculopapular exanthema, urticaria</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal </strong>and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Aggravation of <em>Myasthenia gravis</em>, Lambert-Eaton syndrome and progressive Duchenne muscular dystrophy</p></td><td style="vertical-align:top"><p>Arthralgia, muscular weakness, myalgia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal insufficiency</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system </strong>and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erectile dysfunction, galactorrhoea, gynecomastia</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders </strong>and administration site conditions</p></td><td style="vertical-align:top"><p>Peripheral oedema</p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased blood prolactin levels</p></td></tr></tbody></table><p><br /><sup>1</sup>There was a single post-marketing report on paralysis (tetraparesis) related to the concomitant administration of verapamil and colchicine. This could have been caused by the passage of colchicine through the blood-brain barrier following inhibition of CYP3A4 and P-gp by verapamil (see also section 4.5).</p><p><strong><u>Note</u></strong></p><p>In patients fitted with pacemakers, an increase in the pacing and sensing threshold cannot be ruled out during verapamil therapy.</p><p>In patients with a history of cardiovascular disease, e.g. severe cardiomyopathy, congestive heart failure or recent myocardial infarction, concomitant administration of intravenous beta blockers or disopyramide with intravenous verapamil increased the risk of severe side effects since both substance classes have a cardiodepressive effect (see also section 4.5).</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions :</p><p><strong>To report any side effect(s):</strong></p><p><strong>-National Pharmacovigilance Center (NPC)</strong></p><p><strong>o Fax: +966-11-205-7662</strong></p><p><strong>o SFDA Call Center: 19999</strong></p><p>o <strong>E-mail: npc.drug@sfda.gov.sa</strong></p><p>o <strong>Website: https://ade.sfda.gov.sa</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Symptoms of overdose:</em></strong></p><p>Intoxication symptoms following verapamil poisoning progress depending on the amount ingested, the time at which detoxification measures are applied and the contractile functionality of the myocardium (age-dependent).</p><p>The following symptoms have been observed with severe poisoning:</p><p>Serious hypotension, heart failure, bradycardia or tachycardia arrhythmia (e.g. junctional rhythm with AV dissociation and severe AV block), potentially culminating in cardiovascular shock and cardiac arrest.</p><p>Clouding of consciousness progressing to coma, hyperglycaemia, hypokalaemia, metabolic acidosis, hypoxia, acute respiratory distress syndrome, cardiogenic shock with pulmonary oedema, impaired renal function and convulsions. Deaths have occasionally been reported.</p><p><strong><em>Therapeutic measures in the event of overdose:</em></strong></p><p>Detoxification and restoration of stable cardiovascular conditions are pre-requisite.</p><p>Therapeutic measures depend on the time and method of ingestion, as well as the nature and severity of the intoxication symptoms.</p><p>Gastric lavage is advisable after oral verapamil poisoning, even more than 12 hours after ingestion, if no gastrointestinal motility (bowel sounds) can be detected. If intoxication with sustained-release preparations is suspected, extensive elimination measures are indicated, such as induced vomiting, aspiration of the contents of the stomach and small intestine under endoscopic guidance, intestinal lavage, evacuation, high enema.</p><p>As verapamil cannot be dialysed, haemodialysis is not advisable, but haemofiltration and possibly plasmapheresis (high plasma protein binding of calcium channel blockers) are recommended.</p><p>Standard intensive care resuscitation measures, such as extrathoracic cardiac massage, ventilation, defibrillation and/or pacemaker therapy.</p><p><strong><em>Specific measures:</em></strong></p><p>Elimination of cardiodepressive effects, hypotension and bradycardia.</p><p>Bradycardia arrhythmia is treated symptomatically with atropine and/or beta sympathomimetic agents (isoprenaline, orciprenaline); in the case of life-threatening bradycardia arrhythmia, temporary pacemaker therapy is required. Asystole should be treated by standard methods, including beta adrenergic stimulation (isoprenaline).</p><p>Calcium is a specific antidote, e.g. 10 to 20 ml of a 10% intravenous calcium gluconate solution (2.25 to 4.5 mmol), repeated if necessary, or administered as a continuous drip infusion (e.g. 5 mmol/hour).</p><p>Hypotension, as a result of cardiogenic shock and arterial vasodilation, is treated with dopamine (up to 25 &mu;g per kg of bodyweight per minute), dobutamine (up to 15&mu;g per kg of bodyweight per minute), epinephrine or norepinephrine. The dosage of these medicinal products is guided solely by the effect achieved. Serum calcium should be maintained at high-normal to slightly elevated levels. Additional fluid replacement therapy is administered in the early stages due to arterial vasodilation (Ringer&#39;s or sodium chloride solution).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: selective calcium channel blockers with predominantly cardiac effects, phenyl alkylamine derivatives</p><p>ATC code: C08DA01</p><p><u>Mechanism of action and pharmacodynamic effects</u></p><p>Verapamil hydrochloride belongs to the group of calcium channel blockers. These substances inhibit calcium influx through muscle cell membranes.</p><p>It also acts as a calcium channel blocker on smooth muscle, particularly in the region of the vessels and gastrointestinal tract. The effect on smooth muscle manifests in vasodilation.</p><p>As a calcium channel blocker, verapamil hydrochloride also has a marked effect on the myocardium. The effect on AV nodes is expressed through prolonged conduction time. This can lead to a negative inotropic effect in the working myocardium.</p><p>As a result of vasodilation, a decrease in total peripheral resistance is observed in humans. There is no reflex increase in cardiac output. Consequently, blood pressure drops.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Verapamil hydrochloride is a racemic mixture consisting of equal portions of the R and S enantiomers. Verapamil is extensively metabolised. Norverapamil is one of 12 metabolites that can be detected in the urine; it possesses 10 to 20% of the pharmacological activity of verapamil and accounts for 6% of the excreted active substance.</p><p>The steady-state plasma concentrations of norverapamil and verapamil are comparable. Steady-state is reached after three to four days with repeated daily dosing.</p><p><u>Absorption</u></p><p>Over 90% of verapamil is quickly absorbed from the small intestine following oral administration. The mean systemic availability of the unchanged substance following a single dose of non-sustained-release verapamil is 22% compared to approximately 32% with sustained-release verapamil. This is due to a significant first-pass effect in the liver.</p><p>Bioavailability increases approximately two-fold with repeated dosing. Following the administration of non-sustained-release verapamil, peak plasma concentrations are reached after one to two hours compared to four to five hours after administration of sustained-release verapamil. Norverapamil peak plasma concentrations are reached after one hour (non-sustained-release) or after five hours (sustained-release).</p><p>The bioavailability of verapamil is unaffected if the medicinal product is taken with food.</p><p><u>Distribution</u></p><p>Verapamil is widely distributed in the body tissues; the volume of distribution is 1.8 to 6.8&nbsp;l/kg in healthy subjects. Up to 90% bind to plasma proteins.</p><p><u>Biotransformation</u></p><p>Verapamil is extensively metabolised. <em>In-vitro</em> studies show that verapamil is metabolised by the cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C8, CYP2C9 and CYP2C18. Oral verapamil is extensively metabolised in the liver in healthy men; 12 metabolites have been identified but mostly only in traces. The majority of metabolites consist of various N- and O-dealkylated degradation products of verapamil. Of these, only norverapamil has any notable pharmacological effect (approximately 20% of that of the parent substance); this was seen in a study conducted in dogs.</p><p><u>Elimination</u></p><p>Following intravenous infusion, verapamil is rapidly eliminated bi-exponentially, with a faster early distribution phase (half-life about four minutes) and a slower terminal elimination phase (half-life two to five hours).</p><p>The elimination half-life of oral verapamil is three to seven hours post-dose.</p><p>About 50% of the dose administered is eliminated via the kidneys within 24 hours, and 70% within five days. Up to 16% are excreted with the faeces. About 3 to 4% of the active substance is excreted unchanged via the kidneys. Total clearance is approximately on par with hepatic blood flow, about 1&nbsp;l/h/kg (range: 0.7 to 1.3&nbsp;l/h/kg).</p><p>Considerable inter-individual differences are apparent in terms of clearance.</p><p><strong><em>Special patient groups</em></strong></p><p><u>Paediatric population</u></p><p>Only limited pharmacokinetic data are available regarding use in the paediatric population. Following intravenous administration, the mean half-life was 9.17&nbsp;hours and the average clearance 30&nbsp;l/h compared to 70 l/h in an adult weighing 70 kg. Steady-state plasma concentrations after oral administration appear to be lower in children than in adults.</p><p><u>Elderly patients</u></p><p>Age may influence the pharmacokinetic effects in patients with high blood pressure. The elimination half-life may be prolonged in elderly patients. The anti-hypertensive effect of verapamil is not age-dependent.</p><p><u>Impaired renal function</u></p><p>Impaired renal function does not impact the pharmacokinetic profile of verapamil; this was shown in comparison studies involving end-stage renal failure patients and patients with healthy kidneys.</p><p>Verapamil and norverapamil cannot be removed through haemodialysis.</p><p><u>Impaired hepatic function</u></p><p>The half-life of verapamil is prolonged in patients with impaired hepatic function. This is due to the reduced clearance of the orally administered substance and the increased distribution volume.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Embryonic toxicity studies, not carried out in accordance with current standards, did not reveal any teratogenic effects in rats and rabbits at the highest doses tested (360 mg/m<sup>2</sup> and 180 mg/m<sup>2</sup>, respectively). Maternal toxicity (reduced feed intake and bodyweight gain) and embryo toxicity manifesting in increased embryonic lethality and growth retardation were reported in rats following administration of the highest dose, equivalent to 300 mg/m<sup>2 </sup>in the human therapeutic dosing range. As the highest dose tested in rabbits was far below the human therapeutic dose, the relevance of the study is unclear.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Calcium hydrogen phosphate dihydrate</p><p>&nbsp;croscarmellose sodium</p><p>&nbsp;highly dispersed silicon dioxide</p><p>&nbsp;hypromellose</p><p>&nbsp;macrogol 6000</p><p>magnesium stearate (Ph.Eur.)</p><p>&nbsp;microcrystalline cellulose</p><p>&nbsp;sodium dodecyl sulphate</p><p>talcum</p><p>&nbsp;titanium dioxide (E171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store over 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Original packaging with 20 film-coated tablets</p><p>Original packaging with 50 film-coated tablets</p><p>Original packaging with 100 film-coated tablets</p><p>Clinical pack with &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;40 film-coated tablets</p><p>Clinical pack with &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;160 (4 x 40) film-coated tablets</p><p>Clinical pack with &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;200 (5 x 40) film-coated tablets</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Abbott Laboratories GmbH, 
Hannover, Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>